{"product_id":"sandoz-business-model-canvas","title":"Sandoz Group Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSandoz Group Business Model Canvas: Quick Strategic Playbook for Investors \u0026amp; Founders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Sandoz Group’s business model—this concise Business Model Canvas maps customer segments, value propositions, key partners, and revenue levers that power its generics and biosimilars leadership; ideal for investors, consultants, and founders seeking actionable insights. Download the full Word\/Excel canvas for a detailed, section-by-section playbook to benchmark strategy, inform M\u0026amp;A, or accelerate product-market fit.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Systems and Payors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSandoz partners with national health services and private payors to secure reimbursement and market access, capturing large-volume contracts that offset pricing pressure; in 2024 payor-backed tenders accounted for ~38% of Sandoz’s €8.7bn group sales, stabilizing cash flow. By aligning formularies and outcome-based agreements across 25+ countries by 2025, Sandoz narrows revenue volatility and supports multi-year forecasts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSandoz uses a global network of contract manufacturing organizations (CMOs) to supplement in-house capacity, scaling quickly for biosimilar launches and peak demand for generics; in 2024 Sandoz sourced roughly 28% of finished doses from external partners to manage capacity swings and cut time-to-market by about 20%. Maintaining GMP-level quality and joint audits is critical to meet EMA, FDA and WHO standards and avoid supply disruptions that can cost millions per batch. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic R and D Collaborators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSandoz partners with biotech firms and universities to co-develop complex generics and next‑gen biosimilars, sharing R\u0026amp;D costs and technical risks—Sandoz reported ~€350m R\u0026amp;D spend in 2024 and said collaborations cut development costs by an estimated 20–30%. These alliances keep a pipeline focused on unmet needs in oncology and immunology, where biosimilar launches could save health systems €5–10bn annually by 2028.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale and Retail Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartnerships with global and regional wholesalers ensure Sandoz medicines reach 150,000+ pharmacies and 30,000 hospitals worldwide, using distributors that handled ~€7.1bn of Sandoz product sales in 2024, cutting lead times and cross-border compliance burdens.\u003c\/p\u003e\n\u003cp\u003eThese distributors manage large-volume logistics and cold-chain needs, helping Sandoz keep service levels above 98% and reduce stockout risk for key generics and biosimilars.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCoverage: 150,000+ pharmacies, 30,000 hospitals\u003c\/li\u003e\n\u003cli\u003e2024 distributor-handled sales: ~€7.1bn\u003c\/li\u003e\n\u003cli\u003eTarget service level: \u0026gt;98%\u003c\/li\u003e\n\u003cli\u003eBenefit: lower stockout risk, faster cross-border delivery\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Regulatory Bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSandoz partners with regulators like the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to secure biosimilar approvals; in 2024 Sandoz filed 6 biosimilar MAA\/BLAs and maintained a ~22% share of global biosimilars volume.\u003c\/p\u003e\n\u003cp\u003eEngaging in policy talks lets Sandoz shape interchangeability rules and sustainable pricing; regulatory alignment underpins its legal right to operate and supports generic competition that saved EU healthcare systems ~€33bn in 2023.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e6 biosimilar filings (2024)\u003c\/li\u003e\n\u003cli\u003e~22% global biosimilars volume\u003c\/li\u003e\n\u003cli\u003e€33bn EU savings (2023)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSandoz: €8.7bn sales, 38% payor tenders, €350m R\u0026amp;D, 6 biosimilar filings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSandoz secures payor tenders (~38% of €8.7bn 2024 sales), outsources ~28% of finished doses to CMOs, spent ~€350m on R\u0026amp;D (2024) with ~6 biosimilar filings, and reached \u0026gt;150,000 pharmacies\/30,000 hospitals via distributors handling ~€7.1bn sales, keeping service \u0026gt;98%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup sales\u003c\/td\u003e\n\u003ctd\u003e€8.7bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayor tenders\u003c\/td\u003e\n\u003ctd\u003e~38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributor-handled sales\u003c\/td\u003e\n\u003ctd\u003e€7.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO share finished doses\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e€350m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilar filings\u003c\/td\u003e\n\u003ctd\u003e6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacies\/hospitals\u003c\/td\u003e\n\u003ctd\u003e150,000+\/30,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService level\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for Sandoz Group outlining customer segments, channels, value propositions, key activities, resources, partners, cost structure, and revenue streams, reflecting real-world generics and biosimilars operations and strategic priorities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Sandoz Group’s business model with editable cells—streamlines analysis of manufacturing, generics portfolio, and partnerships to save hours of structuring and enable quick, board-ready insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilar Development and Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSandoz focuses on engineering and clinical testing of biosimilars to replace high-cost biologics, investing over €900m in specialized labs and manufacturing between 2020–2025 and running Phase I–III trials to demonstrate bioequivalence.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 Sandoz has reduced average development time to 5.2 years (from ~7 years in 2018) and cut per-asset clinical spend ~18%, speeding market entry for chronic-disease treatments like insulin analogs and monoclonal antibodies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing of Active Pharmaceutical Ingredients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSandoz runs high-tech API plants that produce chemical and biological inputs for generics and biosimilars, enabling vertical integration that cut procurement costs and improved control over impurity profiles; in 2024 Sandoz reported API-driven gross margin benefits contributing to its €1.9B adjusted EBITDA before synergies for Novartis generics segment, and owning API capacity reduced supplier disruption risk during 2020–24 global shortages by an estimated 30% in supply interruptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Supply Chain and Logistics Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpsandoz manages a global network of warehouses and routes supplying medicines to over countries using demand forecasting inventory optimization align production with local markets in logistics accounted for roughly sandoz cost base helping preserve its low-cost generics margin. efficient transport stock-turn improvements cut lead times by supporting yoy reduction per-unit distribution cost.\u003e\n\u003c\/psandoz\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eContinuous monitoring and auditing of Sandoz Group’s manufacturing ensures each batch matches reference-product safety and efficacy; in 2024 Sandoz reported maintaining GMP (Good Manufacturing Practice) certifications across 30+ sites and completing 1,200+ internal audits to support global approvals.\u003c\/p\u003e\n\u003cp\u003eDedicated compliance teams track regulatory changes across 100+ markets, reducing recall rates—Sandoz cut quality-related recalls by 18% from 2022 to 2024 while sustaining regulatory filing success above 90%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e30+ GMP-certified sites\u003c\/li\u003e\n\u003cli\u003e1,200+ internal audits (2024)\u003c\/li\u003e\n\u003cli\u003e100+ markets monitored\u003c\/li\u003e\n\u003cli\u003e18% fewer recalls (2022–2024)\u003c\/li\u003e\n\u003cli\u003e\u0026gt;90% regulatory filing success\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and Market Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSandoz drives targeted marketing and sales to educate clinicians on its generics and biosimilars, winning hospital formulary listings via tenders and procurement negotiations; after key 2023–2024 patent expiries it captured share quickly, contributing to Sandoz’s €6.5B net sales in 2024 for the generics\/biosimilars segment. \u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocused HCP education and sales targeting\u003c\/li\u003e\n\u003cli\u003eActive tender participation and hospital procurement deals\u003c\/li\u003e\n\u003cli\u003eRapid market entry post-patent expiry—boosting 2024 sales to €6.5B\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSandoz scales biosimilars: €900M capex, 5.2yr dev, €6.5B sales, €1.9B EBITDA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSandoz develops biosimilars and generics, investing \u0026gt;€900m (2020–2025) in labs and manufacturing, running Phase I–III trials and shortening development to 5.2 years by 2025, which cut clinical spend ~18% and sped market entry. It operates 30+ GMP sites, 160+ warehouses to 100+ countries, contributed to €6.5B generics\/biosimilars sales in 2024, and delivered €1.9B adjusted EBITDA (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapEx (2020–25)\u003c\/td\u003e\n\u003ctd\u003e€900m+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevelopment time\u003c\/td\u003e\n\u003ctd\u003e5.2 years (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical spend cut\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGMP sites\u003c\/td\u003e\n\u003ctd\u003e30+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWarehouses\u003c\/td\u003e\n\u003ctd\u003e160+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarkets served\u003c\/td\u003e\n\u003ctd\u003e100+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 sales (generics)\u003c\/td\u003e\n\u003ctd\u003e€6.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 adjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e€1.9B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Sandoz Group Business Model Canvas you'll receive after purchase—no mockup or sample. Upon completing your order, you’ll get this same professionally formatted file, ready to edit and present. What you see is the real deliverable with full content and structure preserved—no surprises, instant access in editable formats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749696156025,"sku":"sandoz-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/sandoz-business-model-canvas.png?v=1772217195","url":"https:\/\/growthsharematrix.com\/products\/sandoz-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}